Clinical trial
A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma
NCT00082082 · SciClone Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00082082 |
|---|---|
| Title | A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma |
| Official title | A Trial of Thymalfasin With Trans Arterial Chemo-Embolization (TACE) in the Treatment of Adult Patients With Unresectable Hepatocellular Carcinoma: A Phase II Trial |
| Lead sponsor | SciClone Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Hepatocellular |
| Intervention type | Drug, Procedure |
| Interventions | Thymalfasin (thymosin alpha-1), Trans arterial chemoembolization (TACE) |
| First posted | Apr 30, 2004 |
| Last update posted | Jan 15, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: